Clinical Trials Directory

Trials / Completed

CompletedNCT02725476

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Xencor, Inc. · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity

Conditions

Interventions

TypeNameDescription
BIOLOGICALXmAb5871

Timeline

Start date
2016-03-01
Primary completion
2017-12-01
Completion
2017-12-01
First posted
2016-04-01
Last updated
2018-12-07
Results posted
2018-12-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02725476. Inclusion in this directory is not an endorsement.